Investing.com - Exicure reported on Monday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Exicure announced earnings per share of $-1.0400 on revenue of $2.02M. Analysts polled by Investing.com EPS of $-0.9000 on revenue of $3.9M.
Exicure 's are down 30% and is trading at $1.2600 , still down 96.25% from its 52 week high of $33.60 set on Monday, November 15, 2021.
Exicure follows other major Healthcare sector earnings this month
Exicure's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar